Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Preparing compound containing saccharide radical
Reexamination Certificate
2007-08-07
2007-08-07
Strzelecka, Teresa E. (Department: 1637)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Preparing compound containing saccharide radical
C435S006120, C536S023100, C536S024300
Reexamination Certificate
active
10618102
ABSTRACT:
The present invention involves the use of quantitative RT-PCR to identify AC133 as a marker. AC133 is prevalent on endothelial progenitor cells (EPCs), which are important cells in angiogenesis. Therefore, the invention is applied to ascertain the quantity of EPCs in a subject, and to diagnose and monitor angiogenesis, for example, in injured tissues and in cancer development and progression.
REFERENCES:
patent: 5776154 (1998-07-01), Taylor et al.
patent: 5843633 (1998-12-01), Yin et al.
patent: 6037129 (2000-03-01), Cole et al.
patent: 6329179 (2001-12-01), Kopreski
patent: 6455678 (2002-09-01), Yin et al.
patent: 2002/0076707 (2002-06-01), Mack et al.
patent: WO 97/41224 (1997-11-01), None
patent: WO 00/55633 (2000-09-01), None
patent: WO 02/059271 (2002-08-01), None
Asahara et al., “VEGF contributes to postnasal neovascularization by mobilizing bone marrow-drived endothelial progenitor cells,”EMBO J., 18(14):3964-3972, 1999.
Bhatia, “AC133 expression in human stem cells,”Leukemia, 15(11):, 1685-1688, 2001.
Boyer et al., “Isolation of endothelial cells and their progenitor cells from human peripheral blood,”J. Vasc. Surg., 31(1-1):181-189, 2000.
Buhring et al., “AC133 antigen expression is not restricted to acute myeloid leukemia blasts but is also found on acute lymphoid leukemia blasts and on a subset of CD34+ B-cell precursosrs,”Blood, 94(2):832-833, 1999.
Byrne and Bundred, “Surrogate markers of tumoral angiogenesis,”Biological Markers, 15(4):334-339, 2000.
Corbeil et al., “The human AC133 hematopoeitic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions,”Journal of Biological Chemistry, 275(8):5512-5520, 2000.
Dimitriou et al., “In vitro proliferative and differentiating characteristics of CD133(+) and CD34(+) cord blood cells in the presence of thrombopoietin (TPO) or erythropoietin (EPO): potential implications for hematopoeitic cell transplantation,”Leukemia Research, 27(12):1143-1151, 2003.
Folkman et al., “Angiogenesis research: guidelines for translation to clinical application,”Thrombosis Haemostasis, 86:23-33, 2001.
Forraz et al., “AC133+ umbilical cord blood progenitor demonstrate rapid self-renewal and low apoptosis,”British Journal of Haematology, 119(2):516-524, 2002.
Gill et al., “Vascular trama induces rapid but transient mobilization of VEGFR2+AC133+ Endothelial precursor cells,”Circ. Res., 88(2):167-174, 2001.
Handgretinger et al., “Biology and plasticity of CD133+ hematopoietic stem cells,”Annals of the New York Academy of Sciences, 996:141-151, 2003.
Hariharan et al., “Human immunodeficiency virus infection of human placental cord blood CD34+AC133+ stem cells and their progeny,”AIDS Res. Hum. Retroviruses, 15(17):1545-1552, 1999.
Hurvitz et al., “Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer(CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-flurouracil, leucovorin) as a first-line therapy in subjects with metastatic CRC,” PRO ASCO Conference, Chicago, Ill., abst #3536, 2003.
Kanayasu-Toyoda et al., “CD31 (PECAM-1)-bright cells derived from AC133-positive cells in human peripheral blood as endothelial-precursor cells,”Journal of Cellular Physiology, 195(1):119-129, 2003.
Lee et al., AC133 antigen as a prognostic factor in acute leukemia,Leukemia Research, 25(9):757-767, 2001.
Marchetti et al., “Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation,”Lab. Invest., 82(6), 2002.
Miraglia et al., “A response to AC133 hematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family?”Blood, 91(11):4390-4391, 1998.
Mundhenke et al., “Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin,”Clinical Cancer Res., 7:3366-3374, 2001.
Nakatani et al., “Circulating endothelial cells in Kawasaki disease,”Clinical&Experimental Immunology, 131(3):536-540, 2003.
Reyes et al., “Origin of endothelial progenitors in human postnatal bone marrow,”J. Clin. Invest., 109(3):337-346, 2002.
Reyes et al., “Purification and ex vivo expansion of postnasal human marrow mesodermal progenitor cells,”Blood, 98(9):2615-2625, 2001.
Salven et al., “VEGFR-3 and CD 133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells,”Blood, 101(1):168-172, 2003.
Schmeisser et al., “Monocytes coexpress endothelial and macrophagocytic linkage markers and form cord-like structures in Matrigel under angiogenic conditions,”Cardiovascular Res., 49:671-680, 2001.
Shi et al., “Influence of nitric oxide synthase II gene disruption on tumor growth and metastasis,”Cancer Res., 60:2579-2583, 2000.
Shi et al., “Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells,”Oncogene, 20:3751-3761, 2001.
Singh et al., “Identification of a cancer stem cell in human brain tumors,”Cancer Res., 63:5821-5828, 2003.
Ueda et al., “DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome,”British Journal of Haematology, 123(2):288-296, 2003.
Vercauteren et al., “CD133 (AC133) expression on AML cells and progenitors,”Cytotherapy, 3(6):449-459, 2001.
Xu et al., “One-step analysis and quantification of RNA by RT-PCR: using high-temperature reverse transcription,”Focus, 22(1):3-5, 2000.
Yin et al., “AC133, a novel marker for human hematopoietic stem and progenitor cells,”Blood, 90(12):5002-5012, 1997.
Yu et al., “AC133-2, a novel isoform of human AC133 stem cell antigen,”Journal of Biological Chemistry, 277(23):20711-20716, 2002.
Mehra et al., “Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases,”Clin. Cancer Res., 12:4859-4866, 2006.
Gallacher et al., “Isolation and characterization of human CD34-Lin- and CD34+ Lin-hematopoietic stem cells using cell surface markers AC133 and CD7,”Blood, 95:2813-2820, 2000.
Lin Edward H.
Wu Xifeng
Xie Keping
Board of Regents the University of Texas System
Fulbright & Jaworski L.L.P.
Strzelecka Teresa E.
LandOfFree
Quantitative RT-PCR to AC133 to diagnose cancer and monitor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quantitative RT-PCR to AC133 to diagnose cancer and monitor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quantitative RT-PCR to AC133 to diagnose cancer and monitor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3895255